Table 2.

Characteristics of trials included in the feasibility assessment and network meta-analysis

Trial ID	Phase	Treatment	Number of patients	Masking	Multicenter	Disease/tumor stage
CALGB 40603[31, 32]	III	Pac + carb➔anthra + cyclo	113	Open-label	Yes	Stage II-III
		Pac + carb + bev➔anthra + cyclo + bev	112
		Pac + bev➔anthra + cyclo + bev	110
		Pac➔anthra + cyclo	108
BrighTNess[34, 35]	III	Pac + carb➔anthra + cyclo	160	Open-label	Yes	Clinical stage T2-3 N0-2 or T1 N1-2
		Pac➔anthra + cyclo	158
		Pac + carb + veli➔anthra + cyclo	316
GeparSepto-GBG 69[22, 23]	III	Pac➔anthra + cyclo	606	Open-label	Yes	cT2—cT4a-d, cT1c and cN + , cT1c and pNSLN + , cT1c and ER-negative and PR-negative, or cT1c and Ki67 > 20%, or cT1c and HER2-positive
		Nab-pac➔anthra + cyclo	606
KEYNOTE-522	III	Pembro + pac + carb➔pembro + anthra + cyclo➔adjuvant pembro	784	Quadruple-blind	Yes	Stage II-III
		Pac + carb➔anthra + cyclo	390
NeoSTOP[33]	II	Pac + carb➔anthra + cyclo	48	Open-label	Yes	Stage I-III
		Doc + carb➔anthra + cyclo	52

Abbreviations: Anthra Anthracycline, bev Bevacizumab, carb Carboplatin; cyclo Cyclophosphamide, doc Docetaxel, dox Doxorubicin, nab-pac Nab-paclitaxel, pac Paclitaxel, pembro Pembrolizumab, veli Veliparib

Arrows (➔) indicate where treatment was administered sequentially; treatments to the left of the arrow were administered first. Anthra includes dox and epi, which were assumed to be equivalent